Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Paul

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Plos Biology|April 4, 2020
BigBrain 3D atlas of cortical layers: Cortical and laminar thickness gradients diverge in sensory and motor corticesKonrad Wagstyl, Stéphanie Larocque, Guillem Cucurull, et al.
Journal for Immunotherapy of Cancer|June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshopGuy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialKei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.
Arrhythmia & Electrophysiology Review|August 30, 2019
British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic MedicationPier D Lambiase, Joseph Paul de Bono, Richard J Schilling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
BMJ Open|June 11, 2021
Protocol for a realist synthesis of health systems responsiveness in low-income and middle-income countriesTolib Mirzoev, Anna Cronin de Chavez, Ana Manzano, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Plos Biology|April 4, 2020
BigBrain 3D atlas of cortical layers: Cortical and laminar thickness gradients diverge in sensory and motor corticesKonrad Wagstyl, Stéphanie Larocque, Guillem Cucurull, et al.
Journal for Immunotherapy of Cancer|June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshopGuy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialKei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.
Arrhythmia & Electrophysiology Review|August 30, 2019
British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic MedicationPier D Lambiase, Joseph Paul de Bono, Richard J Schilling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
BMJ Open|June 11, 2021
Protocol for a realist synthesis of health systems responsiveness in low-income and middle-income countriesTolib Mirzoev, Anna Cronin de Chavez, Ana Manzano, et al.
Pageof 18